2nd Quarter - Report — FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC (2024)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

FRESENIUS KABI USA LLC

Client

FRESENIUS KABI USA LLC

Income

—

Expenses

$554,456

Expense method

A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
2nd Quarter - Report (this page)	Aug 12, 2024	$554,456	Replaced
2nd Quarter - Amendment	Aug 26, 2024	$75,000	Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform

Lobbyist	Covered position, as disclosed
TIMOTHY CASEY	Congressman John Tierney Senator Tom Carper
SARAH CHRISTINE D'ORSIE	Congressman Tom Davis
STEVEN CHASE WALKER New	Congressman Jodey Arrington

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); SENATE; White House Office; Centers For Medicare and Medicaid Services (CMS)

Pharmacy PHA

Rebate reform, any willing pharmacy, PBM reform, IRA Medicare Direct Negotiation, DIR fees

Lobbyist	Covered position, as disclosed
TIMOTHY CASEY	Congressman John Tierney Senator Tom Carper
SARAH CHRISTINE D'ORSIE	Congressman Tom Davis
STEVEN CHASE WALKER New	Congressman Jodey Arrington

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes, patent reform, terminal disclaimers, ancillary product patents

Lobbyist	Covered position, as disclosed
TIMOTHY CASEY	Congressman John Tierney Senator Tom Carper
SARAH CHRISTINE D'ORSIE	Congressman Tom Davis
STEVEN CHASE WALKER New	Congressman Jodey Arrington

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Taxation/Internal Revenue Code TAX

Tax incentives for American production of pharmaceutical product, opioid taxes

Lobbyist	Covered position, as disclosed
TIMOTHY CASEY	Congressman John Tierney Senator Tom Carper
SARAH CHRISTINE D'ORSIE	Congressman Tom Davis
STEVEN CHASE WALKER New	Congressman Jodey Arrington

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.